Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ013
- Development stage
- Preclinical
- Lead developer
- Tuojie Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TJ013 is a small molecule drug candidate developed by Tuojie Biotech (拓界生物医药) that targets Hypoxia-Inducible Factor (HIF). HIF is a transcription factor that plays a pivotal role in the cellular response to hypoxia, regulating genes involved in angiogenesis, cell survival, and metabolism. In the context of oncology, HIF is often overexpressed in the hypoxic environment of solid tumors, contributing to tumor progression and resistance to therapy. TJ013 is designed to modulate this pathway, potentially serving as an antineoplastic agent. It is currently in the early stages of development as part of Tuojie Biotech's small molecule pipeline, which focuses on innovative therapies for cancer and metabolic diseases.
Beyond the preview
Go deeper on TJ013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ013.